The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

Exclusion Criteria

• •* Coronary, peripheral, or carotid revascularization including percutaneous or surgical revascularization in the past 18 months Note: Revascularization procedures can occur in the inpatient or outpatient setting.
• •One of the following:
• •* Low-density lipoprotein (LDL) ≥ 70 mg/dL (1.81 mmol/L) with no plans for immediate initiation or titration of statin therapy (Note: Subjects should not be enrolled into study during initiation/titration of statins until they have a stable LDL-C measurement \> 4 weeks after their last statin change and no immediate plans for future titration).
• •* Newly started on PCSK9i after the index hospitalization/procedure and prior to enrollment (but no more than 6 months prior to enrollment) with pre-PCSK9i treatment LDL-C value available and known background LLT any time prior to PCSK9i initiation.
• •Planned follow-up within the health system.
• •Unable or unwilling to provide informed consent, including but not limited to cognitive or language barriers (reading or comprehension)
• •Lack of phone or email for contact
• •Evidence of end stage renal disease (ESRD) or stage 5 chronic kidney disease (CKD)
• •Anticipated life expectancy less than 6 months
• •On a PCSK9i prior to their qualifying event; Note: Subjects with prior PCSK9i use occurring and ending before the 12-month period prior to enrollment and before the index ASCVD event will be considered for inclusion.
• •EHR Arm Criteria:
• •Subjects are eligible to be included in the "EHR arm" of the registry if they are:
• •Adults age ≥ 40 years of age
• •Have at least 1 inpatient or outpatient diagnosis of clinical ASCVD within 12 months prior to enrollment including CHD, ischemic cerebrovascular disease, atherosclerotic PAD, or prior coronary or peripheral or carotid revascularization.